Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Expert Opin Emerg Drugs. 2024 Apr 12. doi: 10.1080/14728214.2024.2342951. Online ahead of print.ABSTRACTINTRODUCTION: Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large. Even though pharmacotherapy is an integral part of AUD treatment, the few available substances show limited efficacy and limited clinical impact. Thus, there is a need for new innovative pharmacotherapeutic approaches.AREAS COVERED: This paper provides a comprehensive review of drugs approved for the treatment of...
Source: Expert Opinion on Emerging Drugs - April 12, 2024 Category: Drugs & Pharmacology Authors: Sophie K öhne Thomas Hillemacher Alexander Glahn Patrick Bach Source Type: research
Comparison of Pain Management Strategies to Reduce Opioid Use Postoperatively in Free Flap Breast Reconstruction: Pain Catheter versus Nerve Block in Addition to Refinements in the Oral Pain Management Regime
Conclusion Introduction of the CP reduced opioid use and LOS was shorter.PMID:38596158 | PMC:PMC11001454 | DOI:10.1055/s-0043-1777673 (Source: Archives of Plastic Surgery)
Source: Archives of Plastic Surgery - April 10, 2024 Category: Cosmetic Surgery Authors: Andrea B Stefansdottir Luis Vieira Arni Johnsen Daniel Isacson Andres Rodriguez Maria Mani Source Type: research
Therapeutic Drug Monitoring of 6 New-Generation Antiseizure Medications Using a Mass Spectrometry Method: Analysis of 2-Year Experience in a Large Cohort of Korean Epilepsy Patients
CONCLUSIONS.—: A simple and rapid LC-MS/MS method for TDM of 6 ASMs was developed and successfully applied to clinical practice. This large-scale TDM data could help establish an effective monitoring strategy for these drugs.PMID:38576184 | DOI:10.5858/arpa.2023-0386-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 5, 2024 Category: Laboratory Medicine Authors: Sang-Mi Kim Won Young Heo Hyeonju Oh Eun Yeon Joo Young-Min Shon Seung Bong Hong Soo-Youn Lee Dae-Won Seo Source Type: research
Therapeutic Drug Monitoring of 6 New-Generation Antiseizure Medications Using a Mass Spectrometry Method: Analysis of 2-Year Experience in a Large Cohort of Korean Epilepsy Patients
CONCLUSIONS.—: A simple and rapid LC-MS/MS method for TDM of 6 ASMs was developed and successfully applied to clinical practice. This large-scale TDM data could help establish an effective monitoring strategy for these drugs.PMID:38576184 | DOI:10.5858/arpa.2023-0386-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 5, 2024 Category: Laboratory Medicine Authors: Sang-Mi Kim Won Young Heo Hyeonju Oh Eun Yeon Joo Young-Min Shon Seung Bong Hong Soo-Youn Lee Dae-Won Seo Source Type: research
Therapeutic Drug Monitoring of 6 New-Generation Antiseizure Medications Using a Mass Spectrometry Method: Analysis of 2-Year Experience in a Large Cohort of Korean Epilepsy Patients
CONCLUSIONS.—: A simple and rapid LC-MS/MS method for TDM of 6 ASMs was developed and successfully applied to clinical practice. This large-scale TDM data could help establish an effective monitoring strategy for these drugs.PMID:38576184 | DOI:10.5858/arpa.2023-0386-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 5, 2024 Category: Laboratory Medicine Authors: Sang-Mi Kim Won Young Heo Hyeonju Oh Eun Yeon Joo Young-Min Shon Seung Bong Hong Soo-Youn Lee Dae-Won Seo Source Type: research
Diabetic Peripheral Neuropathy: Prevention and Treatment
Am Fam Physician. 2024 Mar;109(3):226-232.ABSTRACTDiabetic peripheral neuropathy occurs in up to 50% of patients with diabetes mellitus and increases the risk of diabetic foot ulcers and infections. Consistent screening and clear communication are essential to decrease disparities in assessment of neuropathic symptoms and diagnosis. Physicians should address underlying risk factors such as poor glycemic control, vitamin B12 deficiency, elevated blood pressure, and obesity to reduce the likelihood of developing neuropathy. First-line drug therapy for painful diabetic peripheral neuropathy includes duloxetine, gabapentin, am...
Source: American Family Physician - April 4, 2024 Category: Primary Care Authors: Scott Bragg Sarah Tucker Marrison Sean Haley Source Type: research
Diabetic Peripheral Neuropathy: Prevention and Treatment
Am Fam Physician. 2024 Mar;109(3):226-232.ABSTRACTDiabetic peripheral neuropathy occurs in up to 50% of patients with diabetes mellitus and increases the risk of diabetic foot ulcers and infections. Consistent screening and clear communication are essential to decrease disparities in assessment of neuropathic symptoms and diagnosis. Physicians should address underlying risk factors such as poor glycemic control, vitamin B12 deficiency, elevated blood pressure, and obesity to reduce the likelihood of developing neuropathy. First-line drug therapy for painful diabetic peripheral neuropathy includes duloxetine, gabapentin, am...
Source: Pain Physician - April 4, 2024 Category: Anesthesiology Authors: Scott Bragg Sarah Tucker Marrison Sean Haley Source Type: research
Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice
This study evaluates the antiallodynic and antihyperalgesic effects of LMH-2, a new haloperidol (HAL) analog that acts as sigma-1 receptor (σ1 R) antagonist, in diabetic mice using a model of neuropathic pain induced by chronic hyperglycemia. Additionally, we compared its effects with those of HAL. Hyperglycemia was induced in mice by nicotinamide-streptozotocin administration (NA-STZ, 50-130 mg/kg). Four weeks later, mechanical allodynia was assessed using the up-down method, and hyperalgesia was evoked with formalin 0.5%. We evaluated antiallodynic and antihyperalgesic effects of LMH-2 (5.6-56.2 mg/kg), HAL (0.018-0.18 ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Rosa Ventura-Mart ínez Guadalupe Esther Ángeles-López Diana Gonz ález-Ugalde Tania Dom ínguez-Páez Gabriel Navarrete-V ázquez Ruth Jaimez Myrna D éciga-Campos Source Type: research
Diabetic Peripheral Neuropathy: Prevention and Treatment
Am Fam Physician. 2024 Mar;109(3):226-232.ABSTRACTDiabetic peripheral neuropathy occurs in up to 50% of patients with diabetes mellitus and increases the risk of diabetic foot ulcers and infections. Consistent screening and clear communication are essential to decrease disparities in assessment of neuropathic symptoms and diagnosis. Physicians should address underlying risk factors such as poor glycemic control, vitamin B12 deficiency, elevated blood pressure, and obesity to reduce the likelihood of developing neuropathy. First-line drug therapy for painful diabetic peripheral neuropathy includes duloxetine, gabapentin, am...
Source: American Family Physician - April 4, 2024 Category: Primary Care Authors: Scott Bragg Sarah Tucker Marrison Sean Haley Source Type: research
Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice
This study evaluates the antiallodynic and antihyperalgesic effects of LMH-2, a new haloperidol (HAL) analog that acts as sigma-1 receptor (σ1 R) antagonist, in diabetic mice using a model of neuropathic pain induced by chronic hyperglycemia. Additionally, we compared its effects with those of HAL. Hyperglycemia was induced in mice by nicotinamide-streptozotocin administration (NA-STZ, 50-130 mg/kg). Four weeks later, mechanical allodynia was assessed using the up-down method, and hyperalgesia was evoked with formalin 0.5%. We evaluated antiallodynic and antihyperalgesic effects of LMH-2 (5.6-56.2 mg/kg), HAL (0.018-0.18 ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Rosa Ventura-Mart ínez Guadalupe Esther Ángeles-López Diana Gonz ález-Ugalde Tania Dom ínguez-Páez Gabriel Navarrete-V ázquez Ruth Jaimez Myrna D éciga-Campos Source Type: research
